{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:53:30Z","timestamp":1784066010144,"version":"3.55.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,5,25]]},"abstract":"<jats:sec id=\"ab-joi210040-4\"><jats:title>Importance<\/jats:title><jats:p>Attention-deficit\/hyperactivity disorder (ADHD) is diagnosed in approximately 2.4% of preschool-age children. Stimulants are recommended as first-line medication treatment. However, up to 25% of preschool-age children with ADHD are treated with \u03b1<jats:sub>2<\/jats:sub>-adrenergic agonist medications, despite minimal evidence about their efficacy or adverse effects in this age range.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi210040-5\"><jats:title>Objective<\/jats:title><jats:p>To determine the frequency of reported improvement in ADHD symptoms and adverse effects associated with \u03b1<jats:sub>2<\/jats:sub>-adrenergic agonists and stimulant medication for initial ADHD medication treatment in preschool-age children.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi210040-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Retrospective electronic health record review. Data were obtained from health records of children seen at 7 outpatient developmental-behavioral pediatric practices in the Developmental Behavioral Pediatrics Research Network in the US. Data were abstracted for 497 consecutive children who were younger than 72 months when treatment with an \u03b1<jats:sub>2<\/jats:sub>-adrenergic agonist or stimulant medication was initiated by a developmental-behavioral pediatrician for ADHD and were treated between January 1, 2013, and July 1, 2017. Follow-up was complete on February 27, 2019.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi210040-7\"><jats:title>Exposures<\/jats:title><jats:p>\u03b1<jats:sub>2<\/jats:sub>-Adrenergic agonist vs stimulant medication as initial ADHD medication treatment.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi210040-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Reported improvement in ADHD symptoms and adverse effects.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi210040-9\"><jats:title>Results<\/jats:title><jats:p>Data were abstracted from electronic health records of 497 preschool-age children with ADHD receiving \u03b1<jats:sub>2<\/jats:sub>-adrenergic agonists or stimulants. Median child age was 62 months at ADHD medication initiation, and 409 children (82%) were males. For initial ADHD medication treatment, \u03b1<jats:sub>2<\/jats:sub>-adrenergic agonists were prescribed to 175 children (35%; median length of \u03b1<jats:sub>2<\/jats:sub>-adrenergic agonist use, 136 days) and stimulants were prescribed to 322 children (65%; median length of stimulant use, 133 days). Improvement was reported in 66% (95% CI,\u200957.5%-73.9%) of children who initiated \u03b1<jats:sub>2<\/jats:sub>-adrenergic agonists and 78% (95% CI, 72.4%-83.4%) of children who initiated stimulants. Only daytime sleepiness was more common for those receiving \u03b1<jats:sub>2<\/jats:sub>-adrenergic agonists vs stimulants (38% vs 3%); several adverse effects were reported more commonly for those receiving stimulants vs \u03b1<jats:sub>2<\/jats:sub>-adrenergic agonists, including moodiness\/irritability (50% vs 29%), appetite suppression (38% vs 7%), and difficulty sleeping (21% vs 11%).<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi210040-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this retrospective review of health records of preschool-age children with ADHD treated in developmental-behavioral pediatric practices, improvement was noted in the majority of children who received \u03b1<jats:sub>2<\/jats:sub>-adrenergic agonists or stimulants, with differing adverse effect profiles between medication classes. Further research, including from randomized clinical trials, is needed to assess comparative effectiveness of \u03b1<jats:sub>2<\/jats:sub>-adrenergic agonists vs stimulants.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2021.6118","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T22:32:00Z","timestamp":1620167520000},"page":"2067","source":"Crossref","is-referenced-by-count":42,"title":["\u03b1<sub>2<\/sub>-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1001","volume":"325","author":[{"given":"Elizabeth","family":"Harstad","sequence":"first","affiliation":[{"name":"Division of Developmental Medicine, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Shults","sequence":"additional","affiliation":[{"name":"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"},{"name":"Perelman School of Medicine at University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Barbaresi","sequence":"additional","affiliation":[{"name":"Division of Developmental Medicine, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Bax","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Sciences Center, Oklahoma City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Cacia","sequence":"additional","affiliation":[{"name":"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Deavenport-Saman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles"},{"name":"Division of General Pediatrics, Children's Hospital Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Friedman","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Children's Hospital Colorado, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"LaRosa","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Loe","sequence":"additional","affiliation":[{"name":"Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Mittal","sequence":"additional","affiliation":[{"name":"Atrium Health, Concord, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Tulio","sequence":"additional","affiliation":[{"name":"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Vanderbilt","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Blum","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine at University of Pennsylvania"},{"name":"Division of Developmental and Behavioral Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"joi210040r1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/15374416.2017.1417860","article-title":"Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016.","volume":"47","author":"Danielson","year":"2018","journal-title":"J Clin Child Adolesc Psychol"},{"issue":"5","key":"joi210040r2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1089\/cap.2007.0075","article-title":"Clinical presentation of attention-deficit\/hyperactivity disorder in preschool children: the Preschoolers with Attention-Deficit\/Hyperactivity Disorder Treatment Study (PATS).","volume":"17","author":"Posner","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"joi210040r3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/jcpp.2005.46.issue-7","article-title":"The impact of preschool inattention, hyperactivity, and impulsivity on social and academic development: a review.","volume":"46","author":"Spira","year":"2005","journal-title":"J Child Psychol Psychiatry"},{"issue":"4","key":"joi210040r4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2528","article-title":"Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents.","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"key":"joi210040r5","doi-asserted-by":"publisher","first-page":"s35","DOI":"10.1097\/DBP.0000000000000770","article-title":"Society for Developmental and Behavioral Pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit\/hyperactivity disorder.","volume":"41","author":"Barbaresi","year":"2020","journal-title":"J Dev Behav Pediatr"},{"issue":"11","key":"joi210040r6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/01.chi.0000235077.32661.61","article-title":"Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.","volume":"45","author":"Greenhill","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"joi210040r7","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1097\/01.chi.0000235082.63156.27","article-title":"Safety and tolerability of methylphenidate in preschool children with ADHD.","volume":"45","author":"Wigal","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"joi210040r8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.5863\/1551-6776-22.6.423","article-title":"Off-label prescribing trends for ADHD medications in very young children.","volume":"22","author":"Panther","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"7","key":"joi210040r9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1089\/cap.2020.0015","article-title":"Epidemiology of treatment for preschoolers on Kentucky Medicaid diagnosed with attention-deficit\/hyperactivity disorder.","volume":"30","author":"Davis","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"joi210040r10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"joi210040r11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jaac.2015.08.016","article-title":"A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit\/hyperactivity disorder.","volume":"54","author":"Wilens","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"joi210040r12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40263-015-0291-6","article-title":"Does guanfacine extended release impact functional impairment in children with attention-deficit\/hyperactivity disorder? results from a randomized controlled trial.","volume":"29","author":"Stein","year":"2015","journal-title":"CNS Drugs"},{"issue":"3","key":"joi210040r13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/(SICI)1097-0355(199723)18:3<300::AID-IMHJ6>3.0.CO;2-Q","article-title":"Clinical experience with guanfacine in 2- and 3-year-old children with attention deficit hyperactivity disorder.","volume":"18","author":"Lee","year":"1997","journal-title":"Infant Ment Health J"},{"issue":"1","key":"joi210040r14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00004583-199501000-00013","article-title":"An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder.","volume":"34","author":"Hunt","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"joi210040r15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/tropej\/fmn117","article-title":"Randomised controlled study-efficacy of clonidine versus carbamazepine in children with ADHD.","volume":"55","author":"Nair","year":"2009","journal-title":"J Trop Pediatr"},{"issue":"1","key":"joi210040r16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/DBP.0b013e31823e05bb","article-title":"The Developmental-Behavioral Pediatrics Research Network: another step in the development of the field.","volume":"33","author":"Blum","year":"2012","journal-title":"J Dev Behav Pediatr"},{"issue":"7","key":"joi210040r17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/DBP.0000000000000585","article-title":"Common use of stimulants and alpha-2 agonists to treat preschool attention-deficit hyperactivity disorder: a DBPNet study.","volume":"39","author":"Blum","year":"2018","journal-title":"J Dev Behav Pediatr"},{"issue":"1","key":"joi210040r18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004703-200602000-00001","article-title":"Long-term stimulant medication treatment of attention-deficit\/hyperactivity disorder: results from a population-based study.","volume":"27","author":"Barbaresi","year":"2006","journal-title":"J Dev Behav Pediatr"},{"issue":"2","key":"joi210040r20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/cap.2019.0105","article-title":"Young children with attention-deficit\/hyperactivity disorder and\/or disruptive behavior disorders are more frequently prescribed alpha agonists than stimulants.","volume":"30","author":"Mittal","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"10","key":"joi210040r21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamapsychiatry.2015.1178","article-title":"A source of false findings in published research studies: adjusting for covariates.","volume":"72","author":"Kraemer","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"joi210040r22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression.","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol Med"},{"issue":"19","key":"joi210040r23","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What\u2019s the relative risk? a method of correcting the odds ratio in cohort studies of common outcomes.","volume":"280","author":"Zhang","year":"1998","journal-title":"JAMA"},{"issue":"17-18","key":"joi210040r24","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1002\/sim.732","article-title":"Applying sample survey methods to clinical trials data.","volume":"20","author":"LaVange","year":"2001","journal-title":"Stat Med"},{"issue":"7","key":"joi210040r26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/DBP.0000000000000329","article-title":"Management of attention-deficit\/hyperactivity disorder by developmental-behavioral pediatricians: a DBPNet study.","volume":"37","author":"Harstad","year":"2016","journal-title":"J Dev Behav Pediatr"},{"key":"joi210040r19","volume-title":"ECDEU Assessment Manual for Psychopharmacolgy, Revised","author":"Guy","year":"1976"},{"key":"joi210040r25","doi-asserted-by":"crossref","DOI":"10.1002\/0471722146","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2000","edition":"2 ed"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2779699\/jama_harstad_2021_oi_210040_1718136091.74678.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T15:00:51Z","timestamp":1718636451000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2779699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":26,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,5,25]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.6118","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,25]]}}}